IL-17-producing T cells contribute to acute graft-versus-host disease in patients undergoing unmanipulated blood and marrow transplantation.
The aim of this study was to investigate the effects of IL-17-producing T cells, including Th17 and Tc17 cells, on acute graft-versus-host disease (aGVHD) in patients who had undergone granulocyte colony-stimulating factor (G-CSF)-mobilised peripheral blood progenitor cell (PBPC) and G-CSF-primed bone marrow (G-BM) transplantation. Allografts from forty-one patients were analysed for IL-17-producing T cells with respect to aGVHD. Furthermore, ten patients with aGVHD onset were monitored for the presence of Th17 cells in the peripheral blood by flow cytometry. Patients who received a higher dose of Th17 cells in the G-BM (>8.5 × 10(4) /kg, p=0.005) or a higher dose of Tc17 cells in PBPC (>16.8 × 10(4) /kg, p=0.001) exhibited a higher incidence of aGVHD. An increased Th17 population (up to 4.99% CD4(+) T lymphocytes) was observed in patients with aGVHD onset. In contrast, the percentage of Th17 population decreased drastically in aGVHD patients following treatment to achieve partial and complete remission (p=0.013 and p=0.008, respectively). All percentages of Th17 and Tc17 cells were significantly reduced after in vivo G-CSF application. Our results suggested that IL-17-producing T cells contributed to aGVHD. The application of G-CSF in vivo aided in reducing the occurrence of aGVHD through a decrease in IL-17 secretion by T cells.
Peking University People's Hospital and Peking University Institute of Haematology, Beijing, PR China.
Xiang-Yu
XY
Zhao
Ling-Ling
LL
Xu
Sheng-Ye
SY
Lu
Xiao-Jun
XJ
Huang
D000293:Adolescent; D000328:Adult; D001769:Blood / Q000187:drug effects; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology* / Q000378:metabolism / Q000637:transplantation; D002452:Cell Count; D002648:Child; D005260:Female; D006086:Graft vs Host Disease / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology* / Q000473:pathology; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D006680:HLA Antigens / Q000276:immunology; D019337:Hematologic Neoplasms / Q000628:therapy; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006648:Histocompatibility / Q000276:immunology; D006801:Humans; D020381:Interleukin-17 / Q000378:metabolism*; D019520:Living Donors; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D012074:Remission Induction; D018417:Th1 Cells / Q000166:cytology / Q000637:transplantation; D058504:Th17 Cells / Q000166:cytology / Q000276:immunology* / Q000637:transplantation; D018418:Th2 Cells / Q000166:cytology / Q000637:transplantation; D014184:Transplantation, Homologous / Q000276:immunology; D055815:Young Adult
D006680:HLA Antigens; D020381:Interleukin-17; D016179:Granulocyte Colony-Stimulating Factor